PDS生物技术公司（PDS Biotechnology Corporation）近日正式对外宣布一项重大战略调整。此次重组表明，公司将把研发重心全力倾斜至其核心候选药物PDS0301之上，目标直指转移性结直肠癌（mCRC）这一严峻的适应症领域。与此同时，针对另一款关键在研产品PDS0101，管理层也已明确规划出一条全新的合作路径，冀望通过外部联盟来加速其临床开发与商业化进程。
PDS生物技术公司（PDS Biotechnology Corporation）近日正式对外宣布一项重大战略调整。此次重组表明，公司将把研发重心全力倾斜至其核心候选药物PDS0301之上，目标直指转移性结直肠癌（mCRC）这一严峻的适应症领域。与此同时，针对另一款关键在研产品PDS0101，管理层也已明确规划出一条全新的合作路径，冀望通过外部联盟来加速其临床开发与商业化进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.